Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patients

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3423-3431

  Bazzoli, C ^a,b   Benech H ^c   Rey, E ^d   Retout, S ^a   Salmon, D ^d   Duval, X ^a,e   Treluyer J M ^d   Mentre F ^a  

^a INSERM   (France)

^b UNIV GRENOBLE ALPES   (France)

^c SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PHOSPHATE; STAVUDINE;

ADULT; ARTICLE; BLOOD SAMPLING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STEADY STATE;

EID: 79959227529     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01487-10     Document Type: Article

References (38)

1. Anderson, P. L., T. N. Kakuda, S. Kawle, and C. V. Fletcher. 2003. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 17:2159-2168.
2. Angel, J. B., et al. 1993. Pharmacokinetics of 3TC (GR109714X) administered with and without food to HIV-infected patients. Clin. Drug Investig. 6:70-74.
3. Aweeka, F. T., et al. 2007. Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team. HIV Med. 8:288-294. (Pubitemid 46901527)
4. Aweeka, F. T., et al. 2006. The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine. AIDS 20:1833-1841. (Pubitemid 44358901)
5. Barry, M. G., et al. 1996. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS 10:1361-1367. (Pubitemid 26333934)
6. Bazzoli, C., et al. 2010. Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin. Pharmacokinet. 49:17-45.
7. Becher, F., et al. 2003. A strategy for liquid chromatography/tandem mass spectrometric assays of intracellular drugs: application to the validation of the triphosphorylated anabolite of antiretrovirals in peripheral blood mononuclear cells. J. Mass Spectrom. 38:879-890. (Pubitemid 37062955)
8. Benech, H., et al. 2004. Peripheral blood mononuclear cell counting using a DNA-detection-based method. Anal. Biochem. 330:172-174.
9. Bertrand, J., E. Comets, and F. Mentre. 2008. Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters. J. Biopharm. Stat. 18:1084-1102.
10. Bertrand, J., et al. 2009. Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART. Eur. J. Clin. Pharmacol. 65:667-678.
11. Carrieri, P., et al. 2001. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. J. Acquir. Immune Defic. Syndr. 28:232-239.
12. Chapman, E. H., A. S. Kurec, and F. R. Davey. 1981. Cell volumes of normal and malignant mononuclear cells. J. Clin. Pathol. 34:1083-1090.
13. Compain, S., L. Durand-Gasselin, J. Grassi, and H. Benech. 2007. Improved method to quantify intracellular zidovudine mono- and triphosphate in peripheral blood mononuclear cells by liquid chromatography-tandem mass spectrometry. J. Mass Spectrom. 42:389-404. (Pubitemid 46426683)
14. Dumond, J. B., et al. 2008. Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men. J. Acquir. Immune Defic. Syndr. 48:156-162.
15. Durand-Gasselin, L., et al. 2008. High levels of zidovudine (AZT) and its intracellular phosphate metabolites in AZT- and AZT-lamivudine-treated newborns of human immunodeficiency virus-infected mothers. Antimicrob. Agents Chemother. 52:2555-2563.
16. Duval, X., et al. 2009. Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART Regimen-ANRS 111 trial. Fundam. Clin. Pharmacol. 23:491-500.
17. Fletcher, C. V., et al. 2000. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS 14:2137-2144.
18. Flynn, P. M., et al. 2007. Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. Antimicrob. Agents Chemother. 51:3516-3522.
19. Gao, W. Y., A. Cara, R. C. Gallo, and F. Lori. 1993. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. U. S. A. 90:8925-8928.
20. Gifford, A. L., et al. 2000. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J. Acquir. Immune Defic. Syndr. 23:386-395.
21. Hirt, D., et al. 2008. Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients. Br. J. Clin. Pharmacol. 65:548-557.
22. Hoggard, P. G., et al. 2001. Zidovudine phosphorylation determined sequentially over 12 months in human immunodeficiency virus-infected patients with or without previous exposure to antiretroviral agents. Antimicrob. Agents Chemother. 45:976-980.
23. Lavielle, M., and F. Mentre. 2007. Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software. J. Pharmacokinet. Pharmacodyn. 34:229-249.
24. Lavielle, M., A. Samson, A. Karina Fermin, and F. Mentré. 2011. Maximum likelihood estimation of long-term HIV dynamic models and antiviral response. Biometrics 67:250-259.
25. Moore, J. D., et al. 2007. Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy. Antivir. Ther. 12:981-986.
26. Moore, K. H., et al. 1999. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS 13:2239-2250. (Pubitemid 29531443)
27. Moore, K. H., et al. 1999. Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption. J. Clin. Pharmacol. 39:593-605.
28. Moore, K. H., et al. 1999. Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. Antimicrob. Agents Chemother. 43:3025-3029.
29. Panhard, X., et al. 2007. Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. Eur. J. Clin. Pharmacol. 63:1019-1029.
30. Rodman, J. H., et al. 1999. Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immunodeficiency virus type 1-infected women and newborn infants. J. Infect. Dis. 180:1844-1850.
31. Samson, A., F. Mentré, and M. Lavielle. 2006. Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: application to HIV dynamics model. Comput. Stat. Data Anal. 51:1562-1574.
32. Segel, G. B., G. R. Cokelet, and M. A. Lichtman. 1981. The measurement of lymphocyte volume: importance of reference particle deformability and counting solution tonicity. Blood 57:894-899.
33. Stretcher, B. N., A. J. Pesce, P. T. Frame, K. A. Greenberg, and D. S. Stein. 1994. Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity. AIDS 8:763-769.
34. Stretcher, B. N., A. J. Pesce, P. T. Frame, and D. S. Stein. 1994. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 38:1541-1547.
35. Stretcher, B. N., A. J. Pesce, P. E. Hurtubise, and P. T. Frame. 1992. Pharmacokinetics of zidovudine phosphorylation in patients infected with the human immunodeficiency virus. Ther. Drug Monit. 14:281-285.
36. Traut, T. W. 1994. Physiological concentrations of purines and pyrimidines. Mol. Cell. Biochem. 140:1-22.
37. Umeh, O. C., and J. S. Currier. 2005. Sex differences in HIV: natural history, pharmacokinetics, and drug toxicity. Curr. Infect. Dis. Rep. 7:73-78.
38. World Health Organization. 30 November 2009, posting date. New WHO recommendations: antiretroviral therapy for adults and adolescents. World Health Organization, Geneva, Switzerland. http://www.who.int/hiv/pub/arv/rapid-advice- art.pdf.